AgingResearch.NewsJoin free

Guangdong Raynovent

CompanyChina

Guangdong Raynovent develops one asset, in phase 2 (RAY1225 in overweight and obesity). Mostly peptide acting on GLP1R and GIPR; based in China.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • RAY1225

    Activates GLP-1 and GIP receptors to improve glycemic control and promote weight loss.

    Phase 2, Peptide, GLP1R, GIPR, overweight and obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals2
  • Similar companies6

Papers

Intelligence